Jagsonpal Pharmaceuticals Ltd
Incorporated in 1978, Jagsonpal Pharmaceuticals Ltd manufactures and trades pharmaceutical products and active pharmaceutical ingredients[1]
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare BSE Allcap
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
| Free Cash Flow |
| CFO/OP |
Ratios
Figures in Rs. Crores
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Insights
In beta| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Doctor Reach (Prescribers) Count ・Standalone data |
|
||
| Number of Distributors (Stockists) Count ・Standalone data |
|||
| Number of Medical Representatives (Field Force) Count ・Standalone data |
|||
| Overall Market Ranking (IQVIA) Rank ・Standalone data |
|||
| Therapeutic Coverage - Gynaecology % ・Standalone data |
|||
| Therapeutic Coverage - Orthopaedics % ・Standalone data |
|||
| Therapeutic Coverage - Dermatology % ・Standalone data |
|||
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
26 Mar - Copy of advertisement published in Newspaper with regard to Postal Ballot Notice sent to the Shareholders of Company.
- Closure of Trading Window 26 Mar
- Shareholder Meeting / Postal Ballot-Notice of Postal Ballot 25 Mar
-
Announcement Under Regulation 30 Of Sebi LODR
13 Mar - Income-tax assessment for AY2024-25: demand Rs.4,81,61,360; company to appeal.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
12 Mar - Announced buyback up to 16 lakh shares at ₹250 totaling ₹40 crore; promoters won't participate.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Jan 2026Transcript PPT REC
-
Jan 2026TranscriptAI SummaryPPT
-
Nov 2025Transcript PPT REC
-
Nov 2025TranscriptAI SummaryPPT
-
Jul 2025Transcript PPT REC
-
Jul 2025TranscriptAI SummaryPPT
-
May 2025Transcript PPT REC
-
May 2025TranscriptAI SummaryPPT
-
Jan 2025Transcript PPT REC
-
Oct 2024Transcript PPT REC
-
Oct 2024TranscriptAI SummaryPPT
-
Aug 2024TranscriptAI SummaryPPT
-
May 2024TranscriptAI SummaryPPT
-
May 2024TranscriptAI SummaryPPT
-
Feb 2024TranscriptAI SummaryPPT
-
Nov 2023TranscriptAI SummaryPPT
-
May 2023TranscriptAI SummaryPPT
-
Feb 2023TranscriptAI SummaryPPT
-
Feb 2022TranscriptAI SummaryPPT
Business Overview:[1][2]
a) JPL provides essential medicines for women-specific healthcare needs, through Gynaecology and Orthopaedics as its focus segments.
b) It is also present in major therapeutic sub-segments viz. antibiotics, allergy management, immunity and cell protection, OTC products, dermatology and pediatrics segment
c) JPL has 17 brands amongst Top 5 brands in the molecule category. It has a pan-India presence through its strong sales team of 900+ individuals. In FY24, company generated ~47% of its revenues from its top 5 brands and ~67% from its top 7 brands